Conference

About

Stay Tuned

Conference

About

Stay Tuned

Pathways to Access Summit (Paths)

Psychedelic Therapeutics in Europe and Beyond

5 June, 2024 | PHIL, Haarlem | The Netherlands

Add-on event the day before ICPR 2024

GET TICKETS

Co-organised by

A Full Day of Insightful Exploration

Watch the video of OPEN Foundation's director explaining the Pathways to Access Summit (Watch till the end!)

Watch the video of OPEN Foundation's director explaining the Pathways to Access Summit

(Watch till the end!)

With the FDA likely approving MDMA-assisted therapy as a treatment for PTSD later this year in the United States, and the evidence supporting the potential of psychedelic therapies further accumulating, 2024 is shaping up to be a pivotal year for the therapeutic use of psychedelics. However, the path to approval and - crucially - patient access in Europe remains uncertain.

The full-day Pathways to Access Summit (Paths) convenes key stakeholders from Europe and beyond to explore the opportunities and challenges around the development, approval, and eventual integration of psychedelic medicines into mainstream European health care.

This summit will unravel the complexities of European regulatory frameworks, addressing the diverse and ever-changing healthcare systems, assessments for pricing and reimbursement, and unique regulatory challenges. We will identify which stakeholders to engage with at each stage of the journey from bench to bedside and share best practices for doing so. We will discuss how to effectively navigate the European regulatory landscape, incorporating insights from other regulatory systems, and offer a well-rounded perspective on the different approaches and best practices to psychedelic medicine regulation.

With growing interest in the potential of psychedelic therapies for mental disorders, understanding the regulatory frameworks and pathways to access of these treatments is now more pertinent than ever.

At the full-day Pathways to Access Summit (PATHS), we will explore what the integration of psychedelic medicines into mainstream European mental health services will entail. During this interactive event, we will delve into the evolving pathways for accessing these innovative treatments, and focusing on safe, timely, and ethical implementation. We will unravel the complexities of European regulatory frameworks, addressing all different stages: from clinical research to reimbursable treatments, which stakeholders to involve in what phase, and how to navigate this process efficiently.

PATHS is a stand-alone event leading up to ICPR, which builds on the insights of the 2022 Psychedelic Science, Ethics & Business Symposium.

Key Questions to be Addressed

With participation from key stakeholders, EU institutions and global experts, this summit will focus on the following questions:

What are the prevalent compliance and availability challenges several nations are presently wrestling with?
What can we learn from different countries and regulatory regimes that might be replicated—or avoided—in the EU?
Similarly, what can we learn from the challenges faced and strategies employed by stakeholders to roll out other first-in-class therapies?
What steps can regulators, drug developers, researchers, and policymakers take today to advance equitable access to psychedelic-assisted treatments?
What are the prevalent compliance and availability challenges several nations are presently wrestling with?
What can we learn from different countries and regulatory regimes that might be replicated—or avoided—in the EU?
Similarly, what can we learn from the challenges faced and strategies employed by stakeholders to roll out other first-in-class therapies?
What steps can regulators, drug developers, researchers, and policymakers take today to advance equitable access to psychedelic-assisted treatments?
What are the prevalent compliance and availability challenges several nations are presently wrestling with?
What can we learn from different countries and regulatory regimes that might be replicated—or avoided—in the EU?
Similarly, what can we learn from the challenges faced and strategies employed by stakeholders to roll out other first-in-class therapies?
What steps can regulators, drug developers, researchers, and policymakers take today to advance equitable access to psychedelic-assisted treatments?
What are the prevalent compliance and availability challenges several nations are presently wrestling with?
What can we learn from different countries and regulatory regimes that might be replicated—or avoided—in the EU?
Similarly, what can we learn from the challenges faced and strategies employed by stakeholders to roll out other first-in-class therapies?
What steps can regulators, drug developers, researchers, and policymakers take today to advance equitable access to psychedelic-assisted treatments?

What are the prevalent compliance and availability challenges several nations are presently wrestling with?
What can we learn from different countries and regulatory regimes that might be replicated—or avoided—in the EU?
Similarly, what can we learn from the challenges faced and strategies employed by stakeholders to roll out other first-in-class therapies?
What steps can regulators, drug developers, researchers, and policymakers take today to advance equitable access to psychedelic-assisted treatments?
What are the prevalent compliance and availability challenges several nations are presently wrestling with?
What can we learn from different countries and regulatory regimes that might be replicated—or avoided—in the EU?
Similarly, what can we learn from the challenges faced and strategies employed by stakeholders to roll out other first-in-class therapies?
What steps can regulators, drug developers, researchers, and policymakers take today to advance equitable access to psychedelic-assisted treatments?
What are the prevalent compliance and availability challenges several nations are presently wrestling with?
What can we learn from different countries and regulatory regimes that might be replicated—or avoided—in the EU?
Similarly, what can we learn from the challenges faced and strategies employed by stakeholders to roll out other first-in-class therapies?
What steps can regulators, drug developers, researchers, and policymakers take today to advance equitable access to psychedelic-assisted treatments?
What are the prevalent compliance and availability challenges several nations are presently wrestling with?
What can we learn from different countries and regulatory regimes that might be replicated—or avoided—in the EU?
Similarly, what can we learn from the challenges faced and strategies employed by stakeholders to roll out other first-in-class therapies?
What steps can regulators, drug developers, researchers, and policymakers take today to advance equitable access to psychedelic-assisted treatments?

What are the prevalent compliance and availability challenges several nations are presently wrestling with?
What can we learn from different countries and regulatory regimes that might be replicated—or avoided—in the EU?
Similarly, what can we learn from the challenges faced and strategies employed by stakeholders to roll out other first-in-class therapies?
What steps can regulators, drug developers, researchers, and policymakers take today to advance equitable access to psychedelic-assisted treatments?
What are the prevalent compliance and availability challenges several nations are presently wrestling with?
What can we learn from different countries and regulatory regimes that might be replicated—or avoided—in the EU?
Similarly, what can we learn from the challenges faced and strategies employed by stakeholders to roll out other first-in-class therapies?
What steps can regulators, drug developers, researchers, and policymakers take today to advance equitable access to psychedelic-assisted treatments?
What are the prevalent compliance and availability challenges several nations are presently wrestling with?
What can we learn from different countries and regulatory regimes that might be replicated—or avoided—in the EU?
Similarly, what can we learn from the challenges faced and strategies employed by stakeholders to roll out other first-in-class therapies?
What steps can regulators, drug developers, researchers, and policymakers take today to advance equitable access to psychedelic-assisted treatments?
What are the prevalent compliance and availability challenges several nations are presently wrestling with?
What can we learn from different countries and regulatory regimes that might be replicated—or avoided—in the EU?
Similarly, what can we learn from the challenges faced and strategies employed by stakeholders to roll out other first-in-class therapies?
What steps can regulators, drug developers, researchers, and policymakers take today to advance equitable access to psychedelic-assisted treatments?

GET TICKETS

‎

Paths Programme

(Download Programme in PDF)

‎

Open Space Sessions

Co-Creating the Future of Psychedelic Medicines

Designed to leverage the innovative concept of Unconferencing, OPEN Space Sessions will allow you, the attendees, to actively participate and shape our agenda, If you have a session idea, you will have a chance to host a session and share your knowledge.

Why are we doing this?

We believe in the collective expertise of our attendees. This interactive approach ensures that Paths not only addresses the predefined topics, but also the pressing issues brought forth by you, the participants.

Empowerment of Participants

Creative & Collaborative Environment

Inclusivity & Diversity

Flexibility & Relevance

Enhanced Networking

How does it work?

If you are interested in hosting a session, you can do so in 2 ways:

On the Day Pitching

At the start of the segment, we will host a pitching session where you can present your session idea, and fellow participants can vote on it.

‎

Online Submission

Prior to the event, you can submit your session idea on our community platform. You and other participants can vote on the ideas.

Submit here soon!

Who is it hosted by?

This part of Paths will be led by Marcus Druen.

He has facilitated highly interactive and invigorating collaboration and authentic relating events for up to 1,500 participants.

Are you ready to co-create the future of psychedelic medicines together?

GET TICKETS

‎

Speakers

Joost Breeksema, PhD

Executive Director & Postdoctoral Researcher

OPEN Foundation & University of Groningen

Tadeusz Hawrot

Founder & Executive Director

Psychedelic Access and Research European Alliance (PAREA)

Amir Inamdar, MBBS, DNB(Psych), MFPM

Chief Medical Officer

Cybin Inc.

‎

…And many more!

See All Speakers

‎

Get the latest updates on speakers, programme and more, including discount tickets by subscribing below to the ICPR Newsletter.

‎

GET TICKETS

Who is Paths for?

This one-day summit is essential for those invested in the future of psychedelic medicines.

Academia

* Clinical scientists / CRO's

* Researchers

* Students

* Clinical scientists / CRO's

* Researchers

* Students

* Clinical scientists / CRO's

* Researchers

* Students

Politics & Society

* Policymakers / Regulators

* Healthcare professionals

* Psychedelic industry professionals

* Patients

* Policymakers / Regulators

* Healthcare professionals

* Psychedelic industry professionals

* Patients

* Policymakers / Regulators

* Healthcare professionals

* Psychedelic industry professionals

* Patients

Business

* Investors

* Insurers

* Executives

* Investors

* Insurers

* Executives

* Investors

* Insurers

* Executives

Practicalities

Date

5th of June, 2024

09:00 - 18:00 CET
The day before ICPR 2024

5th of June, 2024

09:00 - 18:00 CET
The day before ICPR 2024

5th of June, 2024

09:00 - 18:00 CET
The day before ICPR 2024

‎

Location

PHIL, Haarlem
The Netherlands
Same location as ICPR 2024

‎

Questions

Visit FAQ Page

Contact ICPR

‎

Ticketing Options

Tickets

Paths Regular Ticket

€299

In-Person Ticket for Attendees

Includes on-site access to the Pathways to Access Summit on Wednesday.

Full Venue and Programme Access PLUS:

Meet and Network with 300+ Attendees
Badging: Name, Title, Org
Regular OPEN Membership
Access All Recorded Content

Food, Beverages

Coffee, tea, fruits, snacks, water, plus a healthy vegetarian, mainly organic lunch!

Buy Now

ICPR + Paths Package Deals

Professional Package

€1199

Includes:

ICPR Professional Ticket
PATHS Regular Ticket

Buy Now

Standard Package

€849

Includes:

ICPR Regular Ticket
PATHS Regular Ticket

Buy Now

Student Package

€529

Includes:

ICPR Student Ticket
PATHS Regular Ticket

Stay Tuned

Stay Tuned

Pathways to Access Summit (Paths)

Pathways to Access Summit (Paths)

Pathways to Access Summit (Paths)

5 June, 2024 | PHIL, Haarlem | The Netherlands

5 June, 2024 | PHIL, Haarlem | The Netherlands

5 June, 2024 | PHIL, Haarlem | The Netherlands

GET TICKETS

Co-organised by

Co-organised by

A Full Day of Insightful Exploration

A Full Day of Insightful Exploration

A Full Day of Insightful Exploration

Key Questions to be Addressed

GET TICKETS

Paths Programme

Open Space Sessions

Why are we doing this?

Why are we doing this?

Why are we doing this?

Empowerment of Participants

Creative & Collaborative Environment

Inclusivity & Diversity

Flexibility & Relevance

Enhanced Networking

How does it work?

How does it work?

How does it work?

On the Day Pitching

Online Submission

Who is it hosted by?

Who is it hosted by?

Who is it hosted by?

Are you ready to co-create the future of psychedelic medicines together?

Are you ready to co-create the future of psychedelic medicines together?

Are you ready to co-create the future of psychedelic medicines together?

GET TICKETS

Speakers

Joost Breeksema, PhD

Tadeusz Hawrot

Amir Inamdar, MBBS, DNB(Psych), MFPM

Vanina Popova, MD

Martin Gisby

Anne Katrin Schlag, PhD

Elliot Marseille, DrPH, MPP

Paul Liknaitzky, PhD

Alexander Lethen, MBA, BComms

Joost Breeksema, PhD

Tadeusz Hawrot

Amir Inamdar, MBBS, DNB(Psych), MFPM

Joost Breeksema, PhD

Tadeusz Hawrot

Amir Inamdar, MBBS, DNB(Psych), MFPM

Vanina Popova, MD

Martin Gisby

Anne Katrin Schlag, PhD

…And many more!

See All Speakers

GET TICKETS

Who is Paths for?

Academia

Politics & Society

Business

Practicalities

Practicalities

Date

Location

Questions

Ticketing Options

Tickets

Paths Regular Ticket

In-Person Ticket for Attendees

Full Venue and Programme Access PLUS:

Food, Beverages

Buy Now

ICPR + Paths Package Deals

ICPR + Paths Package Deals

Professional Package

Buy Now